NASDAQ:ACRV Acrivon Therapeutics (ACRV) Stock Price, News & Analysis $1.23 -0.10 (-7.52%) Closing price 05/7/2025 04:00 PM EasternExtended Trading$1.22 -0.01 (-0.81%) As of 05/7/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Acrivon Therapeutics Stock (NASDAQ:ACRV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Acrivon Therapeutics alerts:Sign Up Key Stats Today's Range$1.17▼$1.3750-Day Range$1.23▼$5.6152-Week Range$1.17▼$10.16Volume685,836 shsAverage Volume191,788 shsMarket Capitalization$38.57 millionP/E RatioN/ADividend YieldN/APrice Target$19.17Consensus RatingBuy Company OverviewAcrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.Read More… Acrivon Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreACRV MarketRank™: Acrivon Therapeutics scored higher than 68% of companies evaluated by MarketBeat, and ranked 641st out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAcrivon Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAcrivon Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Acrivon Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Acrivon Therapeutics are expected to decrease in the coming year, from ($2.49) to ($2.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acrivon Therapeutics is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acrivon Therapeutics is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcrivon Therapeutics has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Acrivon Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.27% of the float of Acrivon Therapeutics has been sold short.Short Interest Ratio / Days to CoverAcrivon Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Acrivon Therapeutics has recently decreased by 19.91%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAcrivon Therapeutics does not currently pay a dividend.Dividend GrowthAcrivon Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.27% of the float of Acrivon Therapeutics has been sold short.Short Interest Ratio / Days to CoverAcrivon Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Acrivon Therapeutics has recently decreased by 19.91%, indicating that investor sentiment is improving significantly. News and Social Media3.2 / 5News Sentiment0.73 News SentimentAcrivon Therapeutics has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Acrivon Therapeutics this week, compared to 2 articles on an average week.Search Interest3 people have searched for ACRV on MarketBeat in the last 30 days. MarketBeat Follows6 people have added Acrivon Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Acrivon Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,009,858.00 in company stock.Percentage Held by InsidersOnly 8.50% of the stock of Acrivon Therapeutics is held by insiders.Percentage Held by Institutions71.62% of the stock of Acrivon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Acrivon Therapeutics' insider trading history. Receive ACRV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ACRV Stock News HeadlinesInsider Selling: Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Major Shareholder Sells 437,881 Shares of StockMay 2, 2025 | insidertrades.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Major Shareholder Sells $335,841.48 in StockApril 30, 2025 | insidertrades.comNew breed of trader (Wall Street hates us?)Wall Street big wigs and old-money bankers can’t touch this 1 type of stock. And that opens the door for traders like you and me. They couldn’t touch this tech stock that ran from $1.50 to $98.40 in a week. Great – more for us. They wouldn’t touch this little-known imaging company. That’s fine – my friends and I were happy to ride it from $6 to $35 over breakfast.May 8, 2025 | Timothy Sykes (Ad)Piper Sandler Begins Coverage on Acrivon Therapeutics (NASDAQ:ACRV)May 7 at 2:07 AM | americanbankingnews.comFY2025 EPS Estimates for ACRV Boosted by Cantor FitzgeraldMay 4, 2025 | americanbankingnews.comBrokerages Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Target Price at $21.80May 3, 2025 | americanbankingnews.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Down 19.9% in AprilMay 2, 2025 | americanbankingnews.comMajor Shareholder Sells Massive Stake in Acrivon Therapeutics!May 1, 2025 | tipranks.comSee More Headlines ACRV Stock Analysis - Frequently Asked Questions How have ACRV shares performed this year? Acrivon Therapeutics' stock was trading at $6.02 at the beginning of the year. Since then, ACRV stock has decreased by 79.6% and is now trading at $1.23. View the best growth stocks for 2025 here. How were Acrivon Therapeutics' earnings last quarter? Acrivon Therapeutics, Inc. (NASDAQ:ACRV) announced its earnings results on Thursday, March, 27th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.69) by $0.09. When did Acrivon Therapeutics IPO? Acrivon Therapeutics (ACRV) raised $100 million in an initial public offering on Tuesday, November 15th 2022. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, Cowen and Piper Sandler served as the underwriters for the IPO. How do I buy shares of Acrivon Therapeutics? Shares of ACRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Acrivon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Acrivon Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Palo Alto Networks (PANW), ServiceNow (NOW) and Adobe (ADBE). Company Calendar Last Earnings3/27/2025Today5/08/2025Next Earnings (Estimated)5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACRV CIK1781174 Webwww.acrivon.com Phone617-207-8979FaxN/AEmployees58Year FoundedN/APrice Target and Rating Average Stock Price Target$19.17 High Stock Price Target$30.00 Low Stock Price Target$6.00 Potential Upside/Downside+1,458.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-60,390,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-47.95% Return on Assets-43.73% Debt Debt-to-Equity RatioN/A Current Ratio12.75 Quick Ratio12.75 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.38 per share Price / Book0.23Miscellaneous Outstanding Shares31,355,000Free Float28,489,000Market Cap$38.57 million OptionableNot Optionable Beta1.88 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:ACRV) was last updated on 5/8/2025 by MarketBeat.com Staff From Our PartnersURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Seeing how the media and other analysts are covering Trump’s actions – it’s laughable. At least it would be la...Porter & Company | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredVanishing BenefitsWhat would you do if your next Social Security check simply never arrived? If you called and the line was d...Investors Alley | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredUrgent News from my Oceanfront Estate Near Mar-a-LagoFor 40 years, I've had a front-row seat to history's greatest wealth creation events. I spotted Microsoft a...InvestorPlace | SponsoredElon’s Been UpgradedThe New Elon Musk is officially stepping back from his day-to-day duties with DOGE. At least, that's the s...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.